FDA approves Novavax's Nuvaxovid 2025-2026 formula for prevention of COVID-19
Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season
Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season
Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU
Subscribe To Our Newsletter & Stay Updated